FDA Approves Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. — May 23,
Continue reading »
Home »
FDA Approves Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. — May 23,
Continue reading »FDA Approves Elfabrio (pegunigalsidase alfa-iwxj) for the Treatment of Adult Patients with Fabry Disease BOSTON and CARMIEL, Israel, May 10,
Continue reading »PLAINSBORO, NJ, April 28, 2023 – Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved
Continue reading »CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug
Continue reading »Andrew Johnson lets his clients choose what music to play in the car. As an employee of Family Outreach in
Continue reading »Time is running out for free-to-consumer covid vaccines, at-home test kits, and even some treatments. The White House announced this
Continue reading »BOTHELL, Wash.–(BUSINESS WIRE) January 19, 2023 — Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration
Continue reading »When the covid-19 pandemic hit, Dr. Corey Siegel was more prepared than most of his peers. Half of Siegel’s patients
Continue reading »Montana’s conservative leaders, stymied by the courts from passing laws that impose significant statewide abortion restrictions, seek to tighten the
Continue reading »The Host While repealing the Affordable Care Act seems to have fallen off congressional Republicans’ to-do list for 2023, plans
Continue reading »